Polarean Imaging PLC (AIM:POLX, OTC:PLLWF)’s magnetic resource imaging (MRI) contrasting agent has been granted a reimbursement code in the United States, meaning healthcare providers can bill following use of the technology.
The code 'C9791' can be used for healthcare providers to bill public or private insurance programmes for use of the XENOVIEW substance from October, Polarean said in a statement.
“We […] view this as an important step towards enhancing accessibility to this innovative technology,” chief executive Christopher von Jako commented.
XENOVIEW, made from a xenon gas blend, is used to increase contrast in MRI scans of patients’ lungs to evaluate ventilation.
Though the code has been granted by the US Centers for Medicare & Medicaid Services, Polarean is waiting on details of payment levels associated with the technology.
Von Jako suggested this would come “in the coming weeks,” adding: “We look forward to learning the payment details […] as we continue to increase access to XENOVIEW MRI for patients suffering from ventilation-associated lung diseases.”